The proposed mechanistic pathways ensure the significance of TNFR1 and MADD interactions that could be used as a novel target for development of drugs for the treatment of Alzheimer’s disease. Here, TNFRSF1A is linked to early-onset autosomal dominant Alzheimer disease.